论文部分内容阅读
目的探讨COX-2、ERCC-1在卵巢癌组织中的表达及临床病理意义。方法采用组织芯片免疫组化S-P法检测COX-2、ERCC-1在51例卵巢癌组织、15例卵巢良性病变及15例正常卵巢组织中的表达。结果卵巢癌、卵巢囊肿及正常组织COX-2阳性表达率分别为80.3%(40/51)、13.3%(2/15)和6.0%(1/15),ERCC-1阳性表达率为39.2%(20/51)、13.3%(2/15)和0。卵巢癌组织中COX-2的表达与组织学分级、临床分期、淋巴结转移有关(P<0.05),ERCC-1的表达与临床分期、预后有关(P<0.05),两蛋白的表达均与患者年龄、肿块大小无关(均P>0.05)。COX-2与ERCC-1的表达无相关性(r=0.24,P>0.05)。预后≤3年的患者ERCC-1阳性表达程度低于预后>3年的患者。结论卵巢癌组织中COX-2、ERCC-1的阳性表达程度不同,ERCC-1阳性表达程度较高患者预后较好。检测两蛋白可作为卵巢癌预后判断的参考指标。
Objective To investigate the expression of COX-2 and ERCC-1 in ovarian cancer and its clinicopathological significance. Methods The expression of COX-2 and ERCC-1 in 51 cases of ovarian cancer, 15 cases of benign ovarian disease and 15 cases of normal ovarian tissue were detected by immunohistochemistry S-P method. Results The positive rates of COX-2 expression in ovarian cancer, ovarian cyst and normal tissue were 80.3% (40/51), 13.3% (2/15) and 6.0% (1/15) respectively. The positive rate of ERCC-1 expression was 39.2% (20/51), 13.3% (2/15) and 0. The expression of COX-2 in ovarian cancer was correlated with histological grade, clinical stage and lymph node metastasis (P <0.05). The expression of ERCC-1 was correlated with clinical stage and prognosis (P <0.05) Age, size of the tumor had no relationship (all P> 0.05). No correlation was found between the expression of COX-2 and ERCC-1 (r = 0.24, P> 0.05). Patients with a prognosis of ≤3 years had a lower expression of ERCC-1 than those with a prognosis of> 3 years. Conclusions The positive expression of COX-2 and ERCC-1 in ovarian cancer is different, and the prognosis of patients with higher expression of ERCC-1 is better. Detection of two proteins can be used as a prognostic indicator of ovarian cancer.